anti-neoplastic agent as well, when findings indicated that the substance inhibited proliferation and induced differentiation of primitive neuroectodermal tumour cells in vitro and in vivo
. The anti-cancer characteristics of VPA has meanwhile been investigated in pre-clinical models of skin, breast, colon, prostate and small cell lung cancer. Currently, the drug is in phase I trials [4, 5] . It is now recognized that VPA evoked modulations of tumour cell biology (which not only include cell growth and differentiation, but also metastatic and angiogenetic potency) are mediated by HDACinhibition [6, 7] . VPA may, therefore, represent an anti-tumoural compound with great pharmaceutical potential. In fact, among a growing list of HDAC-inhibitors, VPA provides several advantages. It is well tolerated, exhibits low toxicity in adults and, with a halflife of [16] [17] hrs, has suitable pharmacokinetic properties in vivo [8] . However, effective VPA-concentrations used in in vitro culture models are in the range of 1-5 mM; whereas, due to high-plasma protein binding of the drug, the free, active VPA-levels obtained in patients with epilepsy are in the range of 50-200 M. Therefore, the differences between desirable and therapeutically achievable plasma concentrations of VPA may limit its application. With respect to this obstacle, evidence has recently been presented that slight changes in the molecular structure of VPA substantially enhance its efficacy, without influencing the pharmacokinetic properties of the drug [9, 10] . Based on these experiments, we speculated that VPA-derivatives may allow drug application in a lower concentration range.
Organosulphur compounds including allyl isothiocyanate have previously been shown to cause increased acetylation of histones and differentiation in mouse erythroleukaemia cells [11] . In addition, the isothiocyanate sulforaphane has just been identified as an anti-carcinogen that acts on human colon and prostate cancer cells through HDAC-inhibition [12] . Dithiolethiones, like oltipraz ( [13] [14] [15] , and S-methyl methanethiosulfonate, isolated from cauliflower, has been demonstrated to inhibit colon tumour incidence when administered to rats during the post initiation phase of carcinogenesis [16] 
5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione) or anethole trithione (5-(4-methoxyphenyl)-1,2-dithiole-3-thione) are known to exert anti-cancer effects and angiostatic activity

Materials and methods
Cell cultures
ACS2 and ACS33
ACS2 [17] and ACS 33 [18] were supplied by Sulfidris s.r.l., Milano, Italy (Fig. 1) . Both compounds were used in different concentrations and for different time periods, as indicated in results.
Tumour cell growth
Cell proliferation was assessed using the 3- (4,5-dimethylthiazol-2-yl (Fig. 3A) . (Fig. 5) (Fig. 6, right) . (Fig. 6, right) . (Fig. 7) . [19, 20] . Angiogenesis and senescence in prostate tumour cells have also been shown to be influenced by VPA [21] . The bone-invasive potential of prostate cancer in mice is impaired by VPA [22] and appears particularly effective in controlling refractory stages of this disease [23] . [24] . Indeed, dose-limiting toxicities as neurological impairment and febrile neutropenia have been observed in phase I studies [4, 5] . VPA has also been associated with reversible hepatotoxicity and, in few cases, with lethal hepatopathies [25] . Circumvention of the dosage problem can be achieved by structurally modifying VPA. Some of these derivatives exceed the HDAC-inhibition potential 40-fold, compared to the mother compound [9] .
in the 5 day incubation protocol), and significantly more PC3 cells attached to HUVEC than DU-145 cells (Fig. 3A and B). Similar to the growth blocking effects, a 3 day ACS2 pre-incubation at concentrations Ն30 m significantly decreased (but did not completely prevent) adhesion of both DU-145 and PC3 cells to HUVEC. A 5 day preincubation further enhanced the adhesion-blocking effects of ACS2, resulting in very flat adherence curves
ACS33 exerted stronger effects on both tumour cell lines than did ACS2. This was demonstrated by ACS33 concentrations <30 M being sufficient to significantly decrease PC3 or DU-145 attachment to HUVEC (Fig. 3B). Interestingly, pre-incubating the cells for 5 days with ACS33 did not lead to a more pronounced reduction of tumour cell adhesion and flat adherence curves seen with ACS2. Notably, the effect of ACS33 on PC3 cells was even slightly diminished when the drug was applied after 5 days, compared to the 3 day incubation period. Figure 4 demonstrates the influence of ACS33 on the endothelial integrity. In all co-culture experiments carried out with DU-145 or PC3 round openings in the endothelial monolayer in the course of tumour cell binding, due to focal disruptions of intercellular endothelial connections, were observed. Treatment of DU-145 or PC3 cells with ACS33 not only prevented tumour cell adhesion, as described above, but also prevented disruption of the HUVEC monolayer. Similar effects were also seen with respect to ACS2 (data not shown).
ACS2 and ACS33 increase histone H3 and H4 acetylation
DU-145 or PC3 cells were treated with ACS2 or ACS33 for 24 hrs and then histone acetylation was assessed by western blot. Both cell lines showed distinct increases in acetylated H3 and H4 under drug treatment
Furthermore, bcl-2 was down-regulated whereas bax was enhanced, compared to the controls. No differences were seen with respect to integrin ␤1 adhesion receptors and ILK expression. However, Fak and phosphorylated Fak became strongly reduced in tissue specimens of animals treated with ACS33
Immunohistochemistry with antibodies against H3 acetylation demonstrated intense nuclear staining in tumour cells derived from ACS33-treated animals, whereas the immunoreactivity for the proliferation marker MIB was diminished remarkably
Discussion
Several studies have pointed to the important role the HDACinhibitor, VPA, may play in treating prostate cancer. VPA not only down-regulates prostate-specific antigen to basal levels in LNCaP cells, but also mediates the expression of genes relevant to tumour proliferation and apoptosis
Fig. 3 Adhesion of prostate cancer cells to human endothelial cells (HUVEC) is down-regulated by ACS2 (3A) or ACS33 (3B
In this investigation, we report the development of a novel class of HDAC inhibitors, in which VPA was tethered to 5-(4- (Fig. 6, right) . ␤-actin served as the internal control. One representative western blot data of three are shown. [21] . The same dosing schedule was recommended by Xia and coworkers [28] and Gao et al. [29] [9, 30] . Two alkyl groups, branched on the carbon atom C-2 are also obligatory to evoke anti-tumoural effects [31] [8, 33] . An antiangiogenetic activity has already been found for ACS2 [17] .
Fig. 6 Effect of ACS33 on prostate cancer xenografts. PC3 xenografts were established in male athymic mice. Animals in the treatment arm received 20 mg/kg bw ACS33 each day, or 2 mg cisplatin/kg/day (cis-pt). *Indicates significant difference to the control animals. Western blot analysis of H3 and H4 histone expression (total and acetylated), of bcl-2, bax, ILK and Fak (total and activated) was carried out on the tissue specimens using specific antibodies as listed in materials and methods
From a clinical viewpoint, molecular-targeted therapies including both HDAC and angiogenesis inhibition provide promise. Further studies are necessary to understand the molecular background of post-transcriptional modifications and to design specific VPA derivatives to exploit the potential of this class of agents in the treatment of prostate cancer.
